{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:43:52Z","timestamp":1788536632838,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T00:00:00Z","timestamp":1652227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T00:00:00Z","timestamp":1652227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Cancer Center Research and Development Fund","award":["2020-J-3"],"award-info":[{"award-number":["2020-J-3"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Previous studies have suggested that patients with esophageal squamous cell carcinoma (ESCC) are still at a high risk of developing second primary malignancies (SPMs) after definitive therapies. We evaluated the development of SPMs and explored its risk factors in patients with clinical T1bN0 ESCC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>JCOG0502 prospectively compared esophagectomy with definitive chemo-radiotherapy for clinical T1bN0 ESCC. Here, we reviewed all JCOG0502 patients\u2019 data for SPMs and investigated the risk factors for SPMs using uni-variable and multivariable analyses by Fine and Gray model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 379 enrolled patients, 213 underwent esophagectomy and 166 received chemo-radiotherapy. Patient characteristics were male (85%); median age [63 (range 41\u201375) years; location of the primary tumor (upper\/middle\/lower thoracic esophagus, 11%\/63%\/27%, respectively]; alcohol consumption history (79%); smoking history (66%); prevalence of no\/several\/many\/unknown Lugol-voiding lesions (LVLs) (45%\/36%\/8%\/11%, respectively). In a median follow-up of 7.1\u00a0years, 118 SPMs occurred in 99 (26%) patients. Cumulative incidences of SPMs after 3, 5, and 10\u00a0years were 9%, 15%, and 36%, respectively. The most common primary tumor sites were the head and neck (35%), stomach (20%) and lungs (14%). In multivariable analyses, compared to no LVLs, several LVLs [hazard ratio (HR) 2.24, 95% confidential interval (CI) 1.32\u20133.81] and many LVLs (HR 2.88, 95% CI 1.27\u20136.52) were significantly associated with the development of SPMs. Sixteen patients died due to the SPMs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The incidence of SPMs was high. The presence of LVLs, which was a predictive factor for SPMs, may be useful for surveillance planning.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00535-022-01870-y","type":"journal-article","created":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T17:13:47Z","timestamp":1652289227000},"page":"455-463","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Second primary malignancies in patients with clinical T1bN0 esophageal squamous cell carcinoma after definitive therapies: supplementary analysis of the JCOG trial: JCOG0502"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0033-8741","authenticated-orcid":false,"given":"Seiichiro","family":"Mitani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Daiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Nozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Tsunoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigenori","family":"Kadowaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Kadota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryunosuke","family":"Machida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,11]]},"reference":[{"key":"1870_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87\u2013108.","journal-title":"CA Cancer J Clin"},{"key":"1870_CR2","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1053\/j.gastro.2017.08.023","volume":"154","author":"CC Abnet","year":"2018","unstructured":"Abnet CC, Arnold M, Wei WQ. Epidemiology of esophageal squamous cell carcinoma. Gastroenterology. 2018;154:360\u201373.","journal-title":"Gastroenterology"},{"key":"1870_CR3","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10388-019-00674-z","volume":"16","author":"Y Tachimori","year":"2019","unstructured":"Tachimori Y, Ozawa S, Numasaki H, et al. Comprehensive registry of esophageal cancer in Japan. Esophagus. 2019;16:221\u201345.","journal-title":"Esophagus."},{"key":"1870_CR4","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q","volume":"6","author":"DP Slaughter","year":"1953","unstructured":"Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer. 1953;6:963\u20138.","journal-title":"Cancer"},{"key":"1870_CR5","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1002\/cncr.20482","volume":"101","author":"M Muto","year":"2004","unstructured":"Muto M, Nakane M, Katada C, et al. Squamous cell carcinoma in situ at oropharyngeal and hypopharyngeal mucosal sites. Cancer. 2004;101:1375\u201381.","journal-title":"Cancer"},{"key":"1870_CR6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/annonc\/mdy498","volume":"30","author":"K Muro","year":"2019","unstructured":"Muro K, Lordick F, Tsushima T, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS. SSO and TOS Ann Oncol. 2019;30:34\u201343.","journal-title":"SSO and TOS Ann Oncol"},{"key":"1870_CR7","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.jamcollsurg.2005.03.013","volume":"201","author":"Y Sato","year":"2005","unstructured":"Sato Y, Motoyama S, Maruyama K, et al. A second malignancy is the major cause of death among thoracic squamous cell esophageal cancer patients negative for lymph node involvement. J Am Coll Surg. 2005;201:188\u201393.","journal-title":"J Am Coll Surg"},{"key":"1870_CR8","doi-asserted-by":"publisher","first-page":"4336","DOI":"10.1200\/JCO.2003.12.074","volume":"21","author":"T Matsubara","year":"2003","unstructured":"Matsubara T, Yamada K, Nakagawa A. Risk of second primary malignancy after esophagectomy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol. 2003;21:4336\u201341.","journal-title":"J Clin Oncol"},{"key":"1870_CR9","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1007\/s10147-018-1258-7","volume":"23","author":"T Yamaguchi","year":"2018","unstructured":"Yamaguchi T, Kato K, Nagashima K, et al. Type of second primary malignancy after achieving complete response by definitive chemoradiation therapy in patients with esophageal squamous cell carcinoma. Int J Clin Oncol. 2018;23:652\u20138.","journal-title":"Int J Clin Oncol"},{"key":"1870_CR10","doi-asserted-by":"publisher","first-page":"328","DOI":"10.5301\/tj.5000285","volume":"101","author":"WS Hu","year":"2015","unstructured":"Hu WS, Liu ZJ, Zhang JB, et al. Risk patterns of subsequent primary cancers following esophagectomy in early-stage thoracic esophageal squamous cell cancer patients. Tumori. 2015;101:328\u201333.","journal-title":"Tumori"},{"key":"1870_CR11","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/j.1442-2050.2011.01273.x","volume":"25","author":"G Zhu","year":"2012","unstructured":"Zhu G, Chen Y, Zhu Z, et al. Risk of second primary cancer after treatment for esophageal cancer: a pooled analysis of nine cancer registries. Dis Esophagus. 2012;25:505\u201311.","journal-title":"Dis Esophagus"},{"key":"1870_CR12","doi-asserted-by":"publisher","first-page":"e0116384","DOI":"10.1371\/journal.pone.0116384","volume":"10","author":"SC Chen","year":"2015","unstructured":"Chen SC, Teng CJ, Hu YW, et al. Secondary primary malignancy risk among patients with esophageal cancer in Taiwan: a nationwide population-based study. PLoS ONE. 2015;10:e0116384.","journal-title":"PLoS ONE"},{"key":"1870_CR13","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1158\/1055-9965.EPI-07-2876","volume":"17","author":"SC Chuang","year":"2008","unstructured":"Chuang SC, Hashibe M, Scelo G, et al. Risk of second primary cancer among esophageal cancer patients: a pooled analysis of 13 cancer registries. Cancer Epidemiol Biomarkers Prev. 2008;17:1543\u20139.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"1870_CR14","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/cam4.2688","volume":"9","author":"S Mitani","year":"2020","unstructured":"Mitani S, Kadowaki S, Oze I, et al. Risk of second primary malignancies after definitive treatment for esophageal cancer: a competing risk analysis. Cancer Med. 2020;9:394\u2013400.","journal-title":"Cancer Med"},{"key":"1870_CR15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/gut.2009.191080","volume":"59","author":"J Steevens","year":"2010","unstructured":"Steevens J, Schouten LJ, Goldbohm RA, et al. Alcohol consumption, cigarette smoking and risk of subtypes of oesophageal and gastric cancer: a prospective cohort study. Gut. 2010;59:39\u201348.","journal-title":"Gut"},{"key":"1870_CR16","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.7314\/APJCP.2014.15.2.1023","volume":"15","author":"Y Yaegashi","year":"2014","unstructured":"Yaegashi Y, Onoda T, Morioka S, et al. Joint effects of smoking and alcohol drinking on esophageal cancer mortality in Japanese men: findings from the Japan collaborative cohort study. Asian Pac J Cancer Prev. 2014;15:1023\u20139.","journal-title":"Asian Pac J Cancer Prev"},{"key":"1870_CR17","doi-asserted-by":"publisher","first-page":"6414","DOI":"10.1002\/cam4.2514","volume":"8","author":"I Oze","year":"2019","unstructured":"Oze I, Charvat H, Matsuo K, et al. Revisit of an unanswered question by pooled analysis of eight cohort studies in Japan: does cigarette smoking and alcohol drinking have interaction for the risk of esophageal cancer? Cancer Med. 2019;8:6414\u201325.","journal-title":"Cancer Med"},{"key":"1870_CR18","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0016-5107(02)70436-7","volume":"56","author":"M Muto","year":"2002","unstructured":"Muto M, Hironaka S, Nakane M, et al. Association of multiple Lugol-voiding lesions with synchronous and metachronous esophageal squamous cell carcinoma in patients with head and neck cancer. Gastrointest Endosc. 2002;56:517\u201321.","journal-title":"Gastrointest Endosc"},{"key":"1870_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/dote\/doz110","author":"C Katada","year":"2020","unstructured":"Katada C, Yokoyama T, Yano T, et al. Association between the findings of metachronous secondary primary malignancies and the number of Lugol-voiding lesions. Dis Esophagus. 2020. https:\/\/doi.org\/10.1093\/dote\/doz110.","journal-title":"Dis Esophagus"},{"key":"1870_CR20","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1093\/carcin\/bgi035","volume":"26","author":"M Muto","year":"2005","unstructured":"Muto M, Takahashi M, Ohtsu A, et al. Risk of multiple squamous cell carcinomas both in the esophagus and the head and neck region. Carcinogenesis. 2005;26:1008\u201312.","journal-title":"Carcinogenesis"},{"key":"1870_CR21","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1053\/j.gastro.2016.07.040","volume":"151","author":"C Katada","year":"2016","unstructured":"Katada C, Yokoyama T, Yano T, et al. Alcohol consumption and multiple dysplastic lesions increase risk of squamous cell carcinoma in the esophagus, head, and neck. Gastroenterology. 2016;151:860-869.e7.","journal-title":"Gastroenterology"},{"key":"1870_CR22","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.08.007","author":"K Kato","year":"2021","unstructured":"Kato K, Ito Y, Nozaki I, et al. Parallel-group controlled trial of surgery versus chemoradiotherapy in patients with stage I esophageal squamous cell carcinoma. Gastroenterology. 2021. https:\/\/doi.org\/10.1053\/j.gastro.2021.08.007.","journal-title":"Gastroenterology"},{"key":"1870_CR23","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496\u2013509.","journal-title":"J Am Stat Assoc"},{"key":"1870_CR24","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1111\/j.1349-7006.2009.01466.x","volume":"101","author":"K Shitara","year":"2010","unstructured":"Shitara K, Matsuo K, Hatooka S, et al. Heavy smoking history interacts with chemoradiotherapy for esophageal cancer prognosis: a retrospective study. Cancer Sci. 2010;101:1001\u20136.","journal-title":"Cancer Sci"},{"key":"1870_CR25","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1054\/bjoc.2001.2140","volume":"85","author":"V Bagnardi","year":"2001","unstructured":"Bagnardi V, Blangiardo M, La Vecchia C, et al. A meta-analysis of alcohol drinking and cancer risk. Br J Cancer. 2001;85:1700\u20135.","journal-title":"Br J Cancer"},{"key":"1870_CR26","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1093\/jjco\/hyp069","volume":"39","author":"H Kato","year":"2009","unstructured":"Kato H, Sato A, Fukuda H, et al. A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group Study (JCOG9708). Jpn J Clin Oncol. 2009;39:638\u201343.","journal-title":"Jpn J Clin Oncol"},{"key":"1870_CR27","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s10388-015-0511-7","volume":"13","author":"Y Toh","year":"2015","unstructured":"Toh Y, Kitagawa Y, Kuwano H, et al. A nation-wide survey of follow-up strategies for esophageal cancer patients after a curative esophagectomy or a complete response by definitive chemoradiotherapy in Japan. Esophagus. 2015;13:173\u201381.","journal-title":"Esophagus"},{"key":"1870_CR28","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/jjco\/hyaa087","volume":"50","author":"T Shinozaki","year":"2020","unstructured":"Shinozaki T, Katada C, Shiga K, et al. Effectiveness of planned surveillance for detecting second primary head and neck cancers after endoscopic resection of esophageal squamous cell carcinoma. Jpn J Clin Oncol. 2020;50:1162\u20137.","journal-title":"Jpn J Clin Oncol"},{"key":"1870_CR29","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/j.1442-2050.2012.01429.x","volume":"27","author":"C Katada","year":"2014","unstructured":"Katada C, Muto M, Tanabe S, et al. Factors associated with the presence of multiple Lugol-voiding lesions in patients with esophageal squamous-cell carcinoma. Dis Esophagus. 2014;27:457\u201362.","journal-title":"Dis Esophagus"},{"key":"1870_CR30","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1172\/JCI113875","volume":"83","author":"DW Crabb","year":"1989","unstructured":"Crabb DW, Edenberg HJ, Bosron WF, et al. Genotypes for aldehyde dehydrogenase deficiency and alcohol sensitivity. The inactive ALDH2(2) allele is dominant. J Clin Invest. 1989;83:314\u20136.","journal-title":"J Clin Invest"},{"key":"1870_CR31","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41586-018-0811-x","volume":"565","author":"A Yokoyama","year":"2019","unstructured":"Yokoyama A, Kakiuchi N, Yoshizato T, et al. Age-related remodelling of oesophageal epithelia by mutated cancer drivers. Nature. 2019;565:312\u20137.","journal-title":"Nature"},{"key":"1870_CR32","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12885-016-3011-9","volume":"17","author":"FH Morita","year":"2017","unstructured":"Morita FH, Bernardo WM, Ide E, et al. Narrow band imaging versus lugol chromoendoscopy to diagnose squamous cell carcinoma of the esophagus: a systematic review and meta-analysis. BMC Cancer. 2017;17:54.","journal-title":"BMC Cancer"},{"key":"1870_CR33","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1053\/j.gastro.2019.04.017","volume":"157","author":"K Minashi","year":"2019","unstructured":"Minashi K, Nihei K, Mizusawa J, et al. Efficacy of endoscopic resection and selective chemoradiotherapy for Stage I esophageal squamous cell carcinoma. Gastroenterology. 2019;157:382-390.e3.","journal-title":"Gastroenterology"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-022-01870-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-022-01870-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-022-01870-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T16:15:03Z","timestamp":1656087303000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-022-01870-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,11]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1870"],"URL":"https:\/\/doi.org\/10.1007\/s00535-022-01870-y","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,11]]},"assertion":[{"value":"18 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Seiichiro Mitani reports research grants from Taiho Pharmaceutical Co. Ken Kato reports research grants from MSD, Ono Pharmaceutical Co., Merck Serono, Bayer, Beigene, Oncologys Biopharma, Chugai Pharmaceutical Co., and Shionogi. Takashi Kojima reports research grants from Ono Pharmaceutical Co., MSD, Amgen Astellas BioPharma, Chugai Pharmaceutical Co., Shionogi, Parexel, and Taiho Pharmaceutical Co. Yuko Kitagawa is a member of endowed chair from Taiho Pharmaceutical Co., and Chugai Pharmaceutical Co. and reports honorariums from ASAHI KASEI PHARMA Corporation, Taiho Pharmaceutical Co., Ono Pharmaceutical Co., and Chugai Pharmaceutical Co., scholarship grants from Chugai Pharmaceutical Co., Taiho Pharmaceutical Co., Yakult Honsha, ASAHI KASEI PHARMA Corporation, Ohtsuka Pharmaceutical Co., Ltd., and Ono Pharmaceutical Co., trips and other gifts unrelated to research, education, or health care from Ono Pharmaceutical Co. and Bristol Myers Squibb. All remaining authors have declared no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}